Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 10Active not recruiting 9Terminated 2Completed 2Withdrawn 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 5Neoplasm Metastasis 4Myelodysplastic Syndromes 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Osteosarcoma 2Lymphoma, Follicular 2Glioblastoma 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Renal Insufficiency, Chronic 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Multiple Myeloma 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hypogonadism 1HTLV-I Infections 1GATA2 Deficiency 1Eyelid Squamous Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

romidepsin 1olaparib 1durvalumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Urinary Bladder Neoplasms × Specimen Handling × Clear all
NCT03375307 2026-05-13

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

Phase 2 Suspended
60 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡